Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2023 08:00 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients

The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif.,...
January 17, 2023 16:30 ET | Source: Aridis Pharmaceuticals, Inc.

New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 ...